| Literature DB >> 34148733 |
T E F Abbott1, A J Fowler2, T D Dobbs3, J Gibson3, T Shahid2, P Dias2, A Akbari4, I S Whitaker3, R M Pearse2.
Abstract
BACKGROUND: The COVID-19 pandemic has heavily impacted elective and emergency surgery around the world. We aimed to confirm the incidence of perioperative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and associated mortality after surgery.Entities:
Keywords: COVID-19; anaesthesia; epidemiology; public policy; surgery
Mesh:
Year: 2021 PMID: 34148733 PMCID: PMC8192173 DOI: 10.1016/j.bja.2021.05.018
Source DB: PubMed Journal: Br J Anaesth ISSN: 0007-0912 Impact factor: 9.166
Fig 1Inclusion of patients in the analysis.
Patient characteristics. Numbers are presented as n (%) unless otherwise stated. ∗Numbers suppressed to maintain patient anonymity. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; sd, standard deviation; IQR, inter-quartile range; IMD, Index of Multiple Deprivation.
| All patients | SARS-CoV-2 status | |||||
|---|---|---|---|---|---|---|
| None | Preoperative | Perioperative | Postoperative | Any time | ||
| 2 666 978 | 2 638 201 (98.9%) | 18 484 (0.7%) | 2875 (0.1%) | 7418 (0.3%) | 28 777 (1.1%) | |
| Mean ( | 57 (20) | 57 (20) | 62 (18) | 64 (21) | 76 (15) | 65 (20) |
| Median (IQR) | 60 (40–74) | 60 (40–74) | 63 (50–75) | 68 (49–81) | 79 (68–87) | 68 (51–81) |
| Male | 1 182 896 (44.4%) | 1 168 372 (98.8%) | 4279 (0.4%) | 8829 (0.7%) | 1416 (0.1%) | 14 524 (1.2%) |
| Female | 1 483 913 (55.6%) | 1 469 660 (99%) | 3139 (0.2%) | 9655 (0.7%) | 1459 (0.1%) | 14 253 (1%) |
| Unspecified | 169 (0.0%) | 169 (0.0%) | ∗ (%∗) | ∗ (%∗) | ∗ (%∗) | ∗ (%∗) |
| Elective | 1 859 998 (69.7%) | 1 857 586 (99.9%) | 809 (0%) | 1456 (0.1%) | 147 (0%) | 2412 (0.1%) |
| Emergency | 582 292 (21.8%) | 559 374 (96.1%) | 5543 (1%) | 14 721 (2.5%) | 2654 (0.5%) | 22 918 (3.9%) |
| Other | 21 762 (0.8%) | 20 568 (94.5%) | 634 (2.9%) | 491 (2.3%) | 69 (0.3%) | 1194 (5.5%) |
| Maternity | 202 926 (7.6%) | 200 673 (98.9%) | 432 (0.2%) | 1816 (0.9%) | ∗ (%∗) | 2253 (1.1%) |
| Inpatient | 1 343 864 (50.4%) | 1 315 606 (97.9%) | 7049 (0.5%) | 18 337 (1.4%) | 2872 (0.2%) | 28 258 (2.1%) |
| Day-case | 1 323 114 (49.6%) | 1 322 595 (100%) | 369 (0%) | 147 (0%) | ∗ (%∗) | 519 (0%) |
| Score >0 | 1 238 969 (46.5%) | 1 217 783 (98.3%) | 5781 (0.5%) | 12 920 (1%) | 2485 (0.2%) | 21 186 (1.7%) |
| 1 – most deprived | 514 727 (19.3%) | 507 170 (98.5%) | 2109 (0.4%) | 4818 (0.9%) | 630 (0.1%) | 7557 (1.5%) |
| 2 | 526 432 (19.7%) | 520 243 (98.8%) | 1680 (0.3%) | 3966 (0.8%) | 543 (0.1%) | 6189 (1.2%) |
| 3 | 532 351 (20.0%) | 526 934 (99%) | 1361 (0.3%) | 3486 (0.7%) | 570 (0.1%) | 5417 (1%) |
| 4 | 534 211 (20.0%) | 529 434 (99.1%) | 1152 (0.2%) | 3075 (0.6%) | 550 (0.1%) | 4777 (0.9%) |
| 5 – least deprived | 532 808 (20.0%) | 528 280 (99.2%) | 1059 (0.2%) | 2918 (0.5%) | 551 (0.1%) | 4528 (0.8%) |
| Missing IMD status | 26 449 (1.0%) | 26 140 (98.8%) | 57 (0.2%) | 221 (0.8%) | 31 (0.1%) | 309 (1.2%) |
Risk of in-hospital mortality stratified by anatomical location of primary procedure. Data presented as n (%). ∗Numbers suppressed to maintain patient anonymity. Risk of in-hospital mortality stratified by surgical specialty. Organ donation removed given low numbers. GI; gastrointestinal; HPB, hepatopancreatobiliary; LGU, lower genitourinary; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; UGU, upper genitourinary.
| SARS-CoV-2 infection | No SARS-CoV-2 infection | |||
|---|---|---|---|---|
| In-hospital death | In-hospital death | |||
| Bone | 3417 | 815 (23.9%) | 132 180 | 1909 (1.4%) |
| Breast | 43 | ∗ (%∗) | 56 450 | 12 (0.0%) |
| Cardiac | 2374 | 313 (13.2%) | 153 894 | 2609 (1.7%) |
| Cerebrovascular | 116 | 21 (18.1%) | 4769 | 211 (4.4%) |
| Ear | 56 | 10 (17.9%) | 27 756 | 28 (0.1%) |
| Endocrine | 46 | ∗ (%∗) | 14 778 | 32 (0.2%) |
| Female LGU | 48 | ∗ (%∗) | 24 587 | 19 (0.1%) |
| Female UGU | 348 | ∗ (%∗) | 128 201 | 51 (0.0%) |
| HPB | 752 | 120 (16.0%) | 74 445 | 723 (1.0%) |
| Joint | 3067 | 755 (24.6%) | 196 034 | 1860 (0.9%) |
| Lower GI | 2393 | 422 (17.6%) | 227 230 | 2369 (1.0%) |
| Major vessel | 457 | 112 (24.5%) | 19 330 | 819 (4.2%) |
| Male GU | 126 | 19 (15.1%) | 33 521 | 68 (0.2%) |
| Muscle | 157 | 26 (16.6%) | 56 427 | 84 (0.1%) |
| Nasal | 181 | 36 (19.9%) | 48 691 | 106 (0.2%) |
| Neurological | 1675 | 436 (26.0%) | 123 866 | 2654 (2.1%) |
| Obstetrics | 2489 | ∗ (%∗) | 215 432 | 11 (0.0%) |
| Ocular | 133 | ∗ (%∗) | 376 152 | 40 (0.0%) |
| Oral | 130 | 19 (14.6%) | 83 209 | 71 (0.1%) |
| Orthopaedics | 30 | ∗ (%∗) | 13 823 | 11 (0.1%) |
| Other | 395 | 111 (28.1%) | 32 119 | 564 (1.8%) |
| Pharynx | 45 | 9 (20.0%) | 15 182 | 48 (0.3%) |
| Skin | 1475 | 325 (22.0%) | 233 798 | 1059 (0.5%) |
| Skull and spine | 335 | 39 (11.6%) | 62 216 | 279 (0.4%) |
| Thoracic | 4722 | 1503 (31.8%) | 20 185 | 1122 (5.6%) |
| Upper GI | 999 | 258 (25.8%) | 33 128 | 1228 (3.7%) |
| Urological | 978 | 208 (21.3%) | 165 758 | 816 (0.5%) |
| Vascular | 1790 | 562 (31.4%) | 65 040 | 1408 (2.2%) |
Fig 2Top panel: age-adjusted incidence of SARS-CoV-2 infection amongst surgical patients, reported as the number of cases per 100 000 population (y axis on log scale). Bottom panel: weekly rate of death, stratified by SARS-CoV-2 infection status. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Mortality and hospital length of stay, stratified by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection status and acuity of surgery. Data are presented as median (inter-quartile range) or n (%).
| No SARS-CoV-2 | SARS-CoV-2 infection | ||||
|---|---|---|---|---|---|
| Any | Preoperative | Perioperative | Postoperative | ||
| 2 638 201 | 28 777 | 7418 | 18 484 | 2875 | |
| In-hospital death | 20 211 (0.8%) | 6153 (21.4%) | 1544 (20.8%) | 3755 (20.3%) | 854 (29.7%) |
| Length of hospital stay (days) | 0 (0–2) | 13 (4–26) | 9 (2–22) | 12 (4–25) | 23 (15–31) |
| 1 857 586 | 2412 | 809 | 1456 | 147 | |
| In-hospital death | 1414 (0.1%) | 172 (7.1%) | 21 (2.6%) | 125 (8.6%) | 26 (17.7%) |
| Length of hospital stay (days) | 0 (0–1) | 4 (1–16) | 0 (0–3) | 7 (2–20) | 24 (14–33) |
| 559 374 | 22 918 | 5543 | 14 721 | 2654 | |
| In-hospital death | 18 060 (3.2%) | 5752 (25.1%) | 1414 (25.5%) | 3532 (24.0%) | 806 (30.4%) |
| Length of hospital stay (days) | 2 (1–7) | 15 (6–28) | 11 (4–24) | 15 (6–28) | 23 (15–31) |
Multivariable logistic regression analysis for in-hospital mortality within 90 days. Patients with unspecified sex removed before analysis. CI, confidence interval; GI, gastrointestinal; HPB, hepatopancreatobiliary; LGU, lower genitourinary; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; UGU, upper genitourinary.
| Odds ratio | Lower 95% CI | Upper 95% CI | ||
|---|---|---|---|---|
| <0.01 | <0.01 | <0.01 | <0.001 | |
| SARS-CoV-2 code present | 5.7 | 5.5 | 5.91 | <0.001 |
| Female compared with male | 0.81 | 0.79 | 0.83 | <0.001 |
| Age (yr) | 1.03 | 1.03 | 1.04 | <0.001 |
| Cancer present | 1.04 | 1.01 | 1.08 | 0.01 |
| Score 1 | 2.41 | 2.3 | 2.54 | <0.001 |
| Score 2 | 3.72 | 3.53 | 3.92 | <0.001 |
| Score 3 | 5.01 | 4.74 | 5.3 | <0.001 |
| Score 4 | 6.17 | 5.8 | 6.56 | <0.001 |
| Score 5 | 7.07 | 6.57 | 7.61 | <0.001 |
| Score ≥6 | 7.71 | 7.09 | 8.38 | <0.001 |
| Quintile 2 | 0.99 | 0.95 | 1.03 | 0.55 |
| Quintile 3 | 0.94 | 0.9 | 0.98 | <0.001 |
| Quintile 4 | 0.88 | 0.85 | 0.92 | <0.001 |
| Quintile 5 (least deprived) | 0.88 | 0.84 | 0.91 | <0.001 |
| Missing quintile | 1.17 | 1.03 | 1.33 | 0.016 |
| Emergency | 23.54 | 22.33 | 24.83 | <0.001 |
| Maternity | 2.07 | 0.78 | 5.46 | 0.14 |
| Other | 16.59 | 15.2 | 18.08 | <0.001 |
| Breast | 0.23 | 0.14 | 0.38 | <0.001 |
| Cardiac | 0.97 | 0.91 | 1.02 | 0.24 |
| Cerebrovascular | 2.67 | 2.31 | 3.09 | <0.001 |
| Ear | 0.43 | 0.31 | 0.59 | <0.001 |
| Endocrine | 1.32 | 0.94 | 1.86 | 0.107 |
| Female LGU | 0.51 | 0.34 | 0.79 | 0.002 |
| Female UGU | 0.37 | 0.28 | 0.49 | <0.001 |
| HPB | 1.53 | 1.41 | 1.67 | <0.001 |
| Joint | 1.05 | 0.99 | 1.12 | 0.077 |
| Lower GI | 1.73 | 1.63 | 1.83 | <0.001 |
| Major vessel | 2.72 | 2.5 | 2.96 | <0.001 |
| Male GU | 0.69 | 0.55 | 0.87 | 0.001 |
| Muscle | 0.81 | 0.66 | 0.99 | 0.035 |
| Nasal | 0.46 | 0.38 | 0.54 | <0.001 |
| Neuro | 3.46 | 3.26 | 3.66 | <0.001 |
| Obstetrics | 0.31 | 0.12 | 0.77 | 0.012 |
| Ocular | 0.09 | 0.06 | 0.11 | <0.001 |
| Oral | 0.63 | 0.51 | 0.78 | <0.001 |
| Orthopaedics | 0.43 | 0.25 | 0.74 | 0.003 |
| Other | 2.52 | 2.3 | 2.77 | <0.001 |
| Pharynx | 1.71 | 1.3 | 2.26 | <0.001 |
| Skin | 0.83 | 0.77 | 0.89 | <0.001 |
| Skull and spine | 1.38 | 1.22 | 1.56 | <0.001 |
| Thoracic | 5.07 | 4.75 | 5.41 | <0.001 |
| Upper GI | 3.3 | 3.08 | 3.54 | <0.001 |
| Urological | 0.89 | 0.83 | 0.97 | 0.004 |
| Vascular | 1.85 | 1.74 | 1.98 | <0.001 |
Fig 3Kaplan–Meier survival curves stratified by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 status).